[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.12.79. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinicopathologic Reports, Case Reports, and Small Case Series
September 2005

Vision Loss Due to Macular Edema Induced by Rosiglitazone Treatment of Diabetes Mellitus

Arch Ophthalmol. 2005;123(9):1273-1275. doi:10.1001/archopht.123.9.1273

Rosiglitazone is in the thiazolidinedione class of insulin-sensitizing agents used for the treatment of type 2 diabetes mellitus.

Thiazolidinediones have been reported to cause or exacerbate ventricular failure, pulmonary edema, and peripheral edema, especially in patients with left ventricular dysfunction or chronic renal insufficiency.1,2 This case report describes vision loss in a diabetic patient due to rosiglitazone-induced macular edema, which reversed on dosage reduction.

A 55-year-old man noted an insidious decrease in vision in each eye during a 2-week period. He had a history of diabetes mellitus (diagnosed in 1987) complicated by proliferative diabetic retinopathy, neuropathy, and recently discovered nephropathy. Hypertension, hyperlipidemia, and depression were also being treated.

×